Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Печать: 0893-9675
ISSN Онлайн: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v20.i5-6.90
pages 357-371

Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy

Jason H. Tang
Department of Pathology, UCLA David Geffen School of Medicine at UCLA, Los Angeles, CA
David Chia
Department of Pathology, UCLA David Geffen School of Medicine at UCLA, Los Angeles, CA

Краткое описание

Non-small cell lung cancer (NSCLC) still dominates cancer-related deaths in America. Despite this, new discoveries and advancements in technology are helping with the detection and treatment of NSCLC. The discovery of circulating tumor DNA in blood and other biofluids is essential for the creation of a DNA biomarker. Limitations in technology and sequencing have stunted assay development, but with recent advancements in the next-generation sequencing, droplet digital PCR, and EFIRM, the detection of mutations in biofluids has become possible with reasonable sensitivity and specificity. These methods have been applied to the detection of mutations in NSCLC by measuring the levels of circulating tumor DNA. ALK fusion genes along with mutations in EGFR and KRAS have been shown to correlate to tumor size and metastasis. These methods allow for noninvasive, affordable, and efficient diagnoses of oncogenic mutations that overcome the issues of traditional biopsies. These issues include tumor heterogeneity and early detection of cancers with asymptomatic early stages. Early detection and treatment remain the best way to ensure survival. This review aims to describe these new technologies along with their application in mutation detection in NSCLC in order to proactively utilize targeted anticancer therapy.

Ключевые слова: ARMS, BEAMing, ddPCR, EFIRM, liquid biopsies, NSCLC, targeted therapy

Articles with similar content:

From Molecular Tumor Diagnostics to Individualized Treatment with Phytochemicals Derived from Chinese Herbs
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Thomas Efferth
Molecular Mechanisms Underlying the Role of MicroRNAs in Resistance to Epidermal Growth Factor Receptor-Targeted Agents and Novel Therapeutic Strategies for Treatment of Non-Small-Cell Lung Cancer
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 4
Elena Galvani, Godefridus J. Peters, Mina Maftouh, Elisa Giovannetti, Amir Avan
Liquid Biopsies for Assessing Metastatic Melanoma Progression
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 1-2
Dave S.B. Hoon, Kelly Huynh
Targeted Breast Cancer Nanotherapeutics: Options and Opportunities with Estrogen Receptors
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 5
Rishi Paliwal, Govind P Agrawal, Shivani Rai Paliwal, Suresh P. Vyas
Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Yi Ding, Cynthia Reyes-Barron, Paul G. Rothberg, W. Richard Burack